Supplementary Material

## Supplementary Figure1



**Supplementary Figure 1.** Risk score analysis of 3-MRG prognostic signature in the validation cohort 2. (A-D) The risk score, survival status of PC patients, heatmap of the 3-MRG expression, and survival curves between low and high-risk groups were shown. (E) Time-independent ROC analysis of risk score for predicting the OS in the GSE57495 dataset.

## Supplementary Figure2



**Supplementary Figure 2.** Knockdown of NT5E increased chemosensitivity to paclitaxel in Capan-2 and MIA PaCa-2 cells. (A-B) Sensitivity of Capan-2 and MIA PaCa-2 cells to paclitaxel. (C-D) Growth curves of Capan-2 and MIA PaCa-2 cells receiving different treatments.